{"name":"Allgenesis Biotherapeutics Inc.","slug":"allgenesis-biotherapeutics-inc","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"oncology","drugs":[{"name":"AG-80308","genericName":"AG-80308","slug":"ag-80308","indication":"Other","status":"phase_1"}]},{"name":"Oncology","slug":"oncology","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"immunology","drugs":[{"name":"AG-73305","genericName":"AG-73305","slug":"ag-73305","indication":"Advanced solid tumors","status":"phase_2"}]}],"pipeline":[{"name":"AG-80308","genericName":"AG-80308","slug":"ag-80308","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"AG-73305","genericName":"AG-73305","slug":"ag-73305","phase":"phase_2","mechanism":"AG-73305 is a small molecule inhibitor of the PI3K/AKT/mTOR pathway.","indications":["Advanced solid tumors"],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMipwFBVV95cUxOb2gwMlgxV3ZYeHZ6ZmhzZkRDeWgzbHdOeHNQanlVUjNJWm9yVThYVUhaS0VuU0RwRlFIRjZ5MzEtX1p3eDBVODhnLThmcXZJSGVBa0YxT19ScHF1ZnRjVVdiNS1TSkpaUzJCZmdvWHVJaEdSanFVVUNiNTJTc2l6NXlOb0FRTzh0bW1NQU1wT3F3TUszSzRvVlJqYnB3WFR3TGdGRXlTQQ?oc=5","date":"2024-07-28","type":"trial","source":"Ophthalmology Times","summary":"AG-80308 for dry eye disease on track for Phase 2 clinical trial - Ophthalmology Times","headline":"AG-80308 for dry eye disease on track for Phase 2 clinical trial","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMidkFVX3lxTE9CT2syWENOWUh2MnFJX1V5OVVNbDJYZjUtcHkybVNHV2U2bUdINjQ3aEprVU13WW9uMnpHdFZYNmxaNzRmNHNSS2dTUGhJb2dLVGFYYy1XWDNPYlVacFdQVl9kWl9NNmY0M0FaaU1zM2lTc3hFcHc?oc=5","date":"2023-11-29","type":"patent","source":"Patently-O","summary":"Seeing Clearly: Article III Standing of IPR Judicial Review - Patently-O","headline":"Seeing Clearly: Article III Standing of IPR Judicial Review - Patently","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiigFBVV95cUxQcnZSeE9KY21RTDZRQjFaSjh1WHIzOEdDMldVRi1YbktNUUlrbUt6SUtEZ0IzV1o0WktGbHhCSVJfV0V4VWlVQ2dPNkhWZUpXUkI5elJMYkpvc0hHNFhVV2RPYmlYNVZPdC16NGR0di1OUHpfZVA5eC1wVHBBdV93bVh6N3BETFdfOWc?oc=5","date":"2023-11-09","type":"regulatory","source":"Clinical Trials Arena","summary":"Allgenesis reports data from Phase IIa diabetic macular oedema trial - Clinical Trials Arena","headline":"Allgenesis reports data from Phase IIa diabetic macular oedema trial","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMimwFBVV95cUxOOVh5SXpGWnp3Y05mM1BCbWFQOTdlZFRZX3JxQzFOMUtWZXBQVWhZM1NQVk96R01kZE1tZnplVEdMRXMxQ215MVJBZVpEUXg1V3ZhX2VSbndqSXpTX0h0Qmp6NFZCNW1HM1RiT3RWX1l5WEJyX0NhM1NzZTl2Y3FqNkRuVjk5VlZlS0JSbnZtei1XQ0FsV3NpU1F0QQ?oc=5","date":"2023-11-07","type":"trial","source":"Pharmaceutical Technology","summary":"AAO 2023: Allgenesis Biotherapeutics presents Phase IIa data of AG-73305 for DME - Pharmaceutical Technology","headline":"AAO 2023: Allgenesis Biotherapeutics presents Phase IIa data of AG-73305 for DME","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMizwFBVV95cUxOdk5mNnFwenBwN0QyVkprOUFKSlJjYjNLRFN0X3lTaUNmdUhRVW16Rm0xNTF5WnpFQVkxeHVTYkdaVHZ6RjBfczZmTmdvQmQwRHJubjFFYTJqR3ZCNzlHQk1zODJjUWxtRGdHbmVtSmprNEJtRnVIN2Z1Vi1tSjljVkptRjJmSVZjMFZsVkozczgzYzNRU21LWGVqeW9iYU11QXhKd0QyYS1GbDllaGlvejltVHJwMk14RWVYMWFKYlhJdFlVTFZUbWQ5WERNeGs?oc=5","date":"2023-06-19","type":"trial","source":"Ophthalmology Times","summary":"Allgenesis announces Phase 1b data showing AG-80308 providing improvements in dry eye patients - Ophthalmology Times","headline":"Allgenesis announces Phase 1b data showing AG-80308 providing improvements in dry eye patients","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMihgFBVV95cUxPMkk4SFlpeVFJSFV3NXotMHBfMFd6aHJCVzdwdHBoc211V0hxbjRlOTZsb2NneTZDYThDSEhybWhBeTg4UTRISy1USlQ0NC1hMTktak5DZlItQnBWQWtSSjdocGpFYjJCdmdOTlBCQ1dZUlIzVTQzVkdBb0g4ZVhZSGxSc3RkQQ?oc=5","date":"2023-06-19","type":"trial","source":"labiotech.eu","summary":"Allgenesis says dry eye patients’ trial data ‘encouraging’ - labiotech.eu","headline":"Allgenesis says dry eye patients’ trial data ‘encouraging’","sentiment":"neutral"}],"patents":[],"drugCount":2,"phaseCounts":{"phase_1":1,"phase_2":1},"enrichmentLevel":2,"visitCount":2,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}